Viridian's FDA Milestone Raises Questions About Commercial Viability The pharmaceutical industry is abuzz with news that Viridian Therapeutics, Inc. 's (NASDAQ:VRDN) Lumvoa has received FDA approval.
This milestone prompted Wedbush analyst Laura Chico to raise the company's price target to $43, following similar bullish predictions from other analysts.
While investors are undoubtedly excited about the potential for Viridian to capitalize on its FDA milestone, one cannot help but wonder if the company's commercial strategy is as robust as some analysts claim.